DoD Autism, Clinical Translational Research Award | W81XWH 20 ARP CTRA

Opportunity Information: Apply for W81XWH 20 ARP CTRA

The DoD Autism Research Program (ARP) Clinical Translational Research Award is a Department of Defense funding opportunity designed to push autism spectrum disorder (ASD) research closer to real-world clinical impact. It focuses on early-phase, proof-of-principle translational studies that test hypothesis-driven and innovative interventions or clinical approaches intended to address current gaps in ASD care. The central idea is to fund projects that can generate strong preliminary evidence and a clear scientific rationale for later, larger-scale clinical trials that evaluate efficacy more definitively, with the long-term goal of improving and transforming ASD clinical care.

This opportunity prioritizes clinical translational work rather than basic discovery research. Applicants are strongly encouraged to align their projects with the program's stated Areas of Interest for FY20. If a project does not fit one of those areas, it is still potentially eligible, but the application is expected to clearly explain how the work addresses a critical need within the ASD community. In practice, that means proposals should make a convincing case for relevance, feasibility, and near-term clinical value, showing how the study can move the field toward better interventions, better implementation of what already works, or better access and quality of care.

The FY20 Areas of Interest reflect a broad view of ASD needs across the lifespan and across care settings. They include dissemination and implementation of clinically validated interventions, which points to the real problem that even evidence-based practices often fail to reach patients consistently in community settings. They also include behavioral, cognitive, and other non-pharmacological therapies targeting core ASD symptoms or co-occurring conditions, as well as pharmacological, genetic, and other biological treatment approaches aimed at the same outcomes. The opportunity also highlights improving diagnosis and access to services across the lifespan, recognizing that diagnostic pathways, service availability, and continuity of care can vary widely by age, geography, and resources. Another emphasis is interventions that support successful transitions to adulthood, a period where many individuals with ASD encounter reduced service availability and increased demands related to education, employment, independent living, and health care navigation.

A notable feature of the announcement is its attention to health systems and equity. It explicitly calls for healthcare provider-focused training or tools to improve healthcare delivery for individuals with ASD across the lifespan and across the continuum of care, including primary care, urgent and emergent care, and disaster relief contexts. It also highlights cultural, socioeconomic, and gender factors that shape diagnosis, treatment efficacy, delivery, and access to services, signaling an interest in research that can reduce disparities and improve relevance across diverse populations. Finally, the program encourages work that helps explain heterogeneity in treatment response, acknowledging that ASD is highly variable and that differences in response to interventions can be clinically significant and important for personalized care.

Administratively, this is a discretionary federal funding opportunity administered by the Department of Defense, Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA). The funding opportunity number is W81XWH 20 ARP CTRA, and it is listed under CFDA 12.420, which corresponds to military medical research and development activities. The eligible applicant pool is described as unrestricted, meaning a wide range of entity types may apply (subject to any additional eligibility details in the full announcement). Funding instruments available include grants and cooperative agreements, indicating that some awards may involve a more substantial level of involvement or coordination with the funding agency compared to a standard grant mechanism.

For the FY20 cycle referenced in the source, the opportunity was created on February 27, 2020, with an original closing date of July 16, 2020, and it anticipated making about two awards. The award ceiling is shown as 0 in the provided data, which typically indicates that the ceiling was not specified in that particular summary field and would need to be confirmed in the full funding announcement. Overall, the program is best understood as support for well-justified, early clinical translational projects that can credibly set the stage for subsequent rigorous efficacy trials and, ultimately, practical improvements in ASD diagnosis, treatment, and service delivery.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Autism, Clinical Translational Research Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Feb 27, 2020.
• Applicants must submit their applications by Jul 16, 2020. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 2 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 20 ARP CTRA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: